JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan

Shots:

• Dermavant to receive $60M up front, up to $53M as development milestones and royalties on sales of the tapinarof in psoriasis and AD. JT and its subsidiary, Torii Pharmaceutical to get rights to develop & commercialize tapinarof for psoriasis and AD in Japan
• Additionally, JT has signed an exclusive license agreement with Torii to co-develop and commercialize tapinarof in Japan
• Tapinarof (qd) is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA), currently being evaluated in two P-III studies for psoriasis in the US and P-II studies for both psoriasis and AD with its expected NDA filing for PsO to the US FDA in 2021

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Cmocro